Viva Biotech Holdings reported a further on-market share repurchase on 21 May 2026, acquiring 1.20 million ordinary shares at prices between HKD 1.41 and HKD 1.46, for a total consideration of HKD 1.72 million. All repurchased shares are designated for cancellation.

The latest transaction lifts the aggregate number of shares bought back under the mandate approved on 12 June 2025 to 13.42 million, representing 0.63 % of the company’s issued share capital at the time the mandate was granted. The mandate permits a maximum repurchase of 212.84 million shares.

Despite the ongoing buybacks, the company’s issued share capital remained unchanged at 2.13 billion shares as of the close on 21 May 2026 because the repurchased shares had not yet been cancelled. Viva Biotech is subject to a moratorium on new share issues until 20 June 2026, in accordance with Hong Kong listing rules following the repurchase activity.